Clinical

Dataset Information

0

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133


ABSTRACT: RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.

DISEASE(S): Ovarian Tumor,Acute Myeloid And Lymphoid Leukemias,Leukemia, Lymphoid,Brain Tumor,Colorectal Cancer,Liver Cancer,Pancreatic Cancer,Ovarian Neoplasms,Breast Cancer

PROVIDER: 2197463 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-03-25 | GSE227828 | GEO
| 61464 | ecrin-mdr-crc
| 2016592 | ecrin-mdr-crc
| 2141916 | ecrin-mdr-crc
2024-02-12 | GSE249316 | GEO
2018-10-26 | PXD005322 | Pride
| 2002764 | ecrin-mdr-crc
| 2143763 | ecrin-mdr-crc
| 2005296 | ecrin-mdr-crc
| 2740481 | ecrin-mdr-crc